Hepatitis A Vaccine

Identification

Name
Hepatitis A Vaccine
Accession Number
DB10989  (DB10309)
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Description

Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml). 2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and India.

Inactivated hepatitis A vaccines are safe and highly effective. Traditionally, a two-dose schedule is recommended, particularly in travellers at substantial risk of contracting hepatitis A and in immunocompromised individuals. However, in healthy individuals, comparable effectiveness has been achieved with a single dose.

The Chinese live attenuated hepatitis A vaccines have been shown to be safe and highly protective (95%) against clinical infection for at least 3 years. Among the adverse effects from Hepatitis A vaccine injection are fatigue, fever > 99.5°F (37.5°C), induration, redness, and swelling of the injection site and malaise. Anorexia and nausea could be possible side effects.

Synonyms
  • Hepatitis A vaccine, inactivated
Product Ingredients
IngredientUNIICASInChI Key
Hepatitis A virus strain CR 326F antigen (formaldehyde inactivated)Q04Q922K9QNot AvailableNot applicable
Hepatitis A virus strain HM175 antigen (formaldehyde inactivated)5BFC8LZ6LQNot AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AvaximSuspension160 unitIntramuscularSanofi Pasteur Limited1999-05-27Not applicableCanada
Avaxim - Pediatric -(5ml Vial)Suspension800 unitIntramuscularSanofi Pasteur LimitedNot applicableNot applicableCanada
Avaxim - Pediatric -(syringe)Suspension80 unitIntramuscularSanofi Pasteur Limited2003-04-09Not applicableCanada
EpaxalLiquid500 unitIntramuscularBerna Biotech Ltd2000-01-112015-01-01Canada
HavrixInjection, suspension1440 [iU]/mLIntramuscularDispensing Solutions, Inc.2007-04-13Not applicableUs
HavrixInjection, suspension720 [iU]/.5mLIntramuscularGlaxo Smith Kline Biologicals Sa2007-02-16Not applicableUs
HavrixInjection, suspension1440 [iU]/mLIntramuscularA S Medication Solutions2007-04-13Not applicableUs
HavrixInjection, suspension1440 [iU]/mLIntramuscularDispensing Solutions, Inc.2007-04-13Not applicableUs
HavrixInjection, suspension1440 [iU]/mLIntramuscularGlaxo Smith Kline Biologicals Sa2007-04-13Not applicableUs
Havrix - 720unit/ml SusSuspension720 unitIntramuscularGlaxosmithkline Inc1994-12-312001-10-03Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
TwinrixHepatitis A virus strain HM175 antigen (formaldehyde inactivated) (720 [iU]/mL) + Hepatitis B virus subtype ADW2 HBSAG surface protein antigen (20 ug/mL)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals Sa2007-06-07Not applicableUs
TwinrixHepatitis A Vaccine (720 unit) + Hepatitis B Vaccine (Recombinant) (20 mcg)SuspensionIntramuscularGlaxosmithkline Inc1997-09-23Not applicableCanada
TwinrixHepatitis A virus strain HM175 antigen (formaldehyde inactivated) (720 [iU]/mL) + Hepatitis B virus subtype ADW2 HBSAG surface protein antigen (20 ug/mL)Injection, suspensionIntramuscularA S Medication Solutions2007-06-072017-06-20Us
Twinrix JuniorHepatitis A Vaccine (360 unit) + Hepatitis B Vaccine (Recombinant) (10 mcg)SuspensionIntramuscularGlaxosmithkline Inc1998-11-06Not applicableCanada
VivaximHepatitis A Vaccine (160 unit) + Salmonella typhi ty2 vi polysaccharide antigen (25 mcg)Solution; SuspensionIntramuscularSanofi Pasteur Limited2005-11-09Not applicableCanada
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Hepatitis A vaccine is indicated for active immunization against disease caused by hepatitis A virus (HAV). It is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.

HAVRIX® will not prevent hepatitis infection caused by other agents such as hepatitis B virus, hepatitis C virus, hepatitis E virus or other pathogens known to infect the liver. In areas of low to intermediate prevalence of hepatitis A, immunization with HAVRIX® is particularly recommended in subjects who are, or will be, at increased risk of infection such as: * Travelers: Persons traveling to areas where the prevalence of hepatitis A is high. These areas include Africa, Asia, the Mediterranean basin, the Middle East, Central and South America.

  • Armed Forces: Armed Forces personnel who travel to higher endemicity areas or to areas where hygiene is poor have an increased risk of HAV infection. Active immunization is indicated for these individuals.
  • Persons for whom Hepatitis A is an Occupational Hazard: These include employees in day-care centres, nursing, medical and paramedical personnel in hospitals and institutions, especially gastroenterology and pediatric units, sewage workers, and food handlers, among others.
  • Persons for whom there is an Increased Risk of Transmission of Hepatitis A: e.g. homosexuals, persons with multiple sexual partners, abusers of injectable drugs, hemophiliac patients.
  • Contacts of Infected Persons: Since virus shedding of infected persons may occur for a prolonged period, active immunization of close contacts is recommended.
  • Specific Population Groups known to have Higher Incidence of Hepatitis A: e.g. North American Indians, Inuits, recognized community-wide HAV epidemics.
  • Subjects with chronic liver disease or who are at risk of developing chronic liver disease e.g. Hepatitis B (HB) and Hepatitis C (HC) chronic carriers and alcohol abusers.
Structured Indications
Not Available
Pharmacodynamics

Elevation of Anti-Hepatitis A antibodies which gives protection against Hepatitis A infection.

Mechanism of action

The hepatitis A virus belongs to the picornavirus family. It is one of several hepatitis viruses that cause systemic disease with pathology in the liver. The incubation period for hepatitis A averages 28 days (range: 15 to 50 days). The course of hepatitis A infection is extremely variable, ranging from asymptomatic infection to icteric hepatitis and death. The presence of antibodies to HAV confers protection against hepatitis A infection. However, the lowest titer needed to confer protection has not been determined.

Absorption

Vaccine is intended for intramuscular injection. Evaluation of pharmacokinetic properties is not required for vaccines.

Volume of distribution

Evaluation of pharmacokinetic properties is not required for vaccines.

Protein binding

Evaluation of pharmacokinetic properties is not required for vaccines.

Metabolism

Evaluation of pharmacokinetic properties is not required for vaccines.

Route of elimination

Evaluation of pharmacokinetic properties is not required for vaccines.

Half life

Evaluation of pharmacokinetic properties is not required for vaccines.

Clearance

Evaluation of pharmacokinetic properties is not required for vaccines.

Toxicity

Health injuries are not known or expected under normal use. LD50: No data available.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Hepatitis A Vaccine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Hepatitis A Vaccine.Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Hepatitis A Vaccine.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Hepatitis A Vaccine.Experimental, Illicit
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Hepatitis A Vaccine.Approved
AbciximabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Abciximab.Approved
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Hepatitis A Vaccine.Investigational
AbituzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Abituzumab.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Hepatitis A Vaccine.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Hepatitis A Vaccine.Approved
AdecatumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Adecatumumab.Investigational
AdefovirThe risk or severity of adverse effects can be increased when Adefovir is combined with Hepatitis A Vaccine.Investigational
AducanumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Aducanumab.Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Hepatitis A Vaccine.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Hepatitis A Vaccine.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Hepatitis A Vaccine.Experimental, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Hepatitis A Vaccine.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hepatitis A Vaccine.Approved, Investigational
AlicaforsenThe risk or severity of adverse effects can be increased when Alicaforsen is combined with Hepatitis A Vaccine.Investigational
AlirocumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alirocumab.Approved
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Hepatitis A Vaccine.Approved
AmatuximabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Hepatitis A Vaccine.Approved
AMG 108The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with AMG 108.Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Hepatitis A Vaccine.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Hepatitis A Vaccine.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Hepatitis A Vaccine.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Hepatitis A Vaccine.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Hepatitis A Vaccine.Investigational
AnifrolumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Anifrolumab.Investigational
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Hepatitis A Vaccine.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hepatitis A Vaccine.Approved
ApolizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Apolizumab.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Hepatitis A Vaccine.Approved, Investigational
AscrinvacumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ascrinvacumab.Investigational
Asfotase AlfaThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Hepatitis A Vaccine.Investigational
AtezolizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Atezolizumab.Approved, Investigational
AVE9633The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with AVE9633.Investigational
AvelumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Avelumab.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Hepatitis A Vaccine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Hepatitis A Vaccine.Approved
BapineuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bapineuzumab.Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Hepatitis A Vaccine.Approved, Investigational
BavituximabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Hepatitis A Vaccine.Approved, Investigational
BectumomabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bectumomab.Investigational
BegelomabThe risk or severity of adverse effects can be increased when Begelomab is combined with Hepatitis A Vaccine.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Hepatitis A Vaccine.Approved, Investigational
BelimumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Belimumab.Approved
BenznidazoleThe risk or severity of adverse effects can be increased when Benznidazole is combined with Hepatitis A Vaccine.Approved, Investigational
BesilesomabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Besilesomab.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Hepatitis A Vaccine.Approved, Vet Approved
BevacizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bevacizumab.Approved, Investigational
BIIB015The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with BIIB015.Investigational
BimagrumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bimagrumab.Investigational
BivatuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bivatuzumab.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Hepatitis A Vaccine.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Hepatitis A Vaccine.Approved, Investigational
BlosozumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Blosozumab.Investigational
BococizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bococizumab.Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Hepatitis A Vaccine.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Briakinumab is combined with Hepatitis A Vaccine.Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Hepatitis A Vaccine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Hepatitis A Vaccine.Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Hepatitis A Vaccine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hepatitis A Vaccine.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Hepatitis A Vaccine.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Hepatitis A Vaccine.Approved, Investigational
CaplacizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Caplacizumab.Investigational
Capromab pendetideThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Capromab pendetide.Approved
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Hepatitis A Vaccine.Approved
CarlumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Carlumab.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Hepatitis A Vaccine.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Hepatitis A Vaccine.Experimental
CatumaxomabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Catumaxomab.Approved, Investigational, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Hepatitis A Vaccine.Approved
CetuximabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Hepatitis A Vaccine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Hepatitis A Vaccine.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Hepatitis A Vaccine.Approved
CixutumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cixutumumab.Investigational
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Hepatitis A Vaccine.Approved, Investigational
ClazakizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clazakizumab.Investigational
ClenoliximabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clenoliximab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Hepatitis A Vaccine.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Hepatitis A Vaccine.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Hepatitis A Vaccine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Hepatitis A Vaccine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Hepatitis A Vaccine.Approved, Investigational
Coltuximab ravtansineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Coltuximab ravtansine.Investigational
ConatumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Conatumumab.Investigational
ConcizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Concizumab.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Hepatitis A Vaccine.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Hepatitis A Vaccine.Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Hepatitis A Vaccine.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Hepatitis A Vaccine.Approved, Investigational
CR002The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with CR002.Investigational
CrenezumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Crenezumab.Investigational
CrotedumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Crotedumab.Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Hepatitis A Vaccine.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hepatitis A Vaccine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Hepatitis A Vaccine.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Hepatitis A Vaccine.Approved, Investigational
DacetuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Hepatitis A Vaccine.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Hepatitis A Vaccine.Approved, Investigational
DalotuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daratumumab.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Hepatitis A Vaccine.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Hepatitis A Vaccine.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Hepatitis A Vaccine.Approved, Investigational
DemcizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Demcizumab.Investigational
DenosumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Hepatitis A Vaccine.Investigational
DepatuxizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Depatuxizumab.Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Hepatitis A Vaccine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Hepatitis A Vaccine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Hepatitis A Vaccine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Hepatitis A Vaccine.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hepatitis A Vaccine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Hepatitis A Vaccine.Vet Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Hepatitis A Vaccine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Hepatitis A Vaccine.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Hepatitis A Vaccine.Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Hepatitis A Vaccine.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Hepatitis A Vaccine.Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hepatitis A Vaccine.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Hepatitis A Vaccine.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Hepatitis A Vaccine.Approved, Investigational
DulaglutideThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dulaglutide.Approved, Investigational
DuligotuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Duligotuzumab.Investigational
DupilumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Durvalumab.Approved, Investigational
DusigitumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dusigitumab.Investigational
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Hepatitis A Vaccine.Approved, Investigational
EdrecolomabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Edrecolomab.Experimental, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Efalizumab is combined with Hepatitis A Vaccine.Approved, Investigational
EldelumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Eldelumab.Investigational
ElotuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Emibetuzumab.Investigational
EmicizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Emicizumab.Approved, Investigational
EnokizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Enokizumab.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Hepatitis A Vaccine.Approved
EpratuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Hepatitis A Vaccine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Hepatitis A Vaccine.Approved
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Hepatitis A Vaccine.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Hepatitis A Vaccine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Hepatitis A Vaccine.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Hepatitis A Vaccine.Approved, Investigational
EtaracizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Etaracizumab.Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Hepatitis A Vaccine.Approved
EtrolizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Hepatitis A Vaccine.Approved
EvolocumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ficlatuzumab.Investigational
FigitumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Figitumumab.Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Hepatitis A Vaccine.Approved, Investigational
FirategrastThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Firategrast.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Hepatitis A Vaccine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Hepatitis A Vaccine.Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Hepatitis A Vaccine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Hepatitis A Vaccine.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Hepatitis A Vaccine.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Hepatitis A Vaccine.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Hepatitis A Vaccine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Hepatitis A Vaccine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Hepatitis A Vaccine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Hepatitis A Vaccine.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Hepatitis A Vaccine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Hepatitis A Vaccine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Hepatitis A Vaccine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Hepatitis A Vaccine.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Hepatitis A Vaccine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Hepatitis A Vaccine.Approved
FontolizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Hepatitis A Vaccine.Approved, Investigational, Withdrawn
FresolimumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fulranumab.Investigational
GaliximabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with Hepatitis A Vaccine.Approved, Investigational
GanitumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ganitumab.Investigational
GantenerumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gantenerumab.Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Hepatitis A Vaccine.Approved
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hepatitis A Vaccine.Approved, Investigational
GevokizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gevokizumab.Investigational
Glatiramer AcetateThe risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Hepatitis A Vaccine.Approved, Investigational
Glembatumumab vedotinThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Glembatumumab vedotin.Investigational
GlimepirideThe risk or severity of adverse effects can be increased when Glimepiride is combined with Hepatitis A Vaccine.Approved
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Hepatitis A Vaccine.Approved
GS 0573The risk or severity of adverse effects can be increased when GS 0573 is combined with Hepatitis A Vaccine.Investigational
GuselkumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Guselkumab.Approved, Investigational
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Hepatitis A Vaccine.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Hepatitis A Vaccine.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Hepatitis A Vaccine.Investigational
Human C1-esterase inhibitorThe risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Hepatitis A Vaccine.Approved
Human cytomegalovirus immune globulinThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Human cytomegalovirus immune globulin.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hepatitis A Vaccine.Approved, Vet Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Hepatitis A Vaccine.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Hepatitis A Vaccine.Investigational
IbalizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibalizumab.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hepatitis A Vaccine.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Hepatitis A Vaccine.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Hepatitis A Vaccine.Approved, Investigational
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Hepatitis A Vaccine.Approved
IdarucizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Idarucizumab.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Hepatitis A Vaccine.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Hepatitis A Vaccine.Approved
IGN311The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with IGN311.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Hepatitis A Vaccine.Approved
IMC-1C11The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with IMC-1C11.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Hepatitis A Vaccine.Approved, Investigational
Immune Globulin HumanThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Immune Globulin Human.Approved, Investigational
InclacumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Inclacumab.Investigational
Indium In-111 satumomab pendetideThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Indium In-111 satumomab pendetide.Approved, Withdrawn
InebilizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Inebilizumab.Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Hepatitis A Vaccine.Approved
Inotuzumab ozogamicinThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Inotuzumab ozogamicin.Approved, Investigational
IntetumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Intetumumab.Investigational
IPH 2101The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with IPH 2101.Investigational
IpilimumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ipilimumab.Approved
IratumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Iratumumab.Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hepatitis A Vaccine.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Hepatitis A Vaccine.Investigational
IxekizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ixekizumab.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Hepatitis A Vaccine.Approved, Investigational, Nutraceutical
LabetuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lampalizumab.Investigational
LandogrozumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Landogrozumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Hepatitis A Vaccine.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Hepatitis A Vaccine.Approved
LerdelimumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lerdelimumab.Investigational
LexatumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lexatumumab.Investigational
LigelizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ligelizumab.Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Hepatitis A Vaccine.Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Hepatitis A Vaccine.Approved, Investigational
Lorvotuzumab mertansineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lorvotuzumab mertansine.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Hepatitis A Vaccine.Approved
LucatumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lucatumumab.Investigational
LumiliximabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lumiliximab.Investigational
MatuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Matuzumab.Investigational
MavrilimumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mavrilimumab.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Hepatitis A Vaccine.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Hepatitis A Vaccine.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Hepatitis A Vaccine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Hepatitis A Vaccine.Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Hepatitis A Vaccine.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Hepatitis A Vaccine.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Hepatitis A Vaccine.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Hepatitis A Vaccine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hepatitis A Vaccine.Approved, Vet Approved
MilatuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Milatuzumab.Investigational
Mirvetuximab SoravtansineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Hepatitis A Vaccine.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Hepatitis A Vaccine.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Hepatitis A Vaccine.Investigational
MogamulizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mogamulizumab.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Hepatitis A Vaccine.Approved, Vet Approved
MotavizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Motavizumab.Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Hepatitis A Vaccine.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Hepatitis A Vaccine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hepatitis A Vaccine.Approved
MYO-029The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with MYO-029.Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Hepatitis A Vaccine.Approved, Investigational
Naptumomab EstafenatoxThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Naptumomab Estafenatox.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Hepatitis A Vaccine.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Hepatitis A Vaccine.Investigational
NebacumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Nebacumab.Experimental
NecitumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Necitumumab.Approved, Investigational
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Hepatitis A Vaccine.Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Hepatitis A Vaccine.Approved, Investigational
NimotuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Nimotuzumab.Investigational
NivolumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Hepatitis A Vaccine.Approved, Investigational
OcrelizumabThe therapeutic efficacy of Ocrelizumab can be decreased when used in combination with Hepatitis A Vaccine.Approved, Investigational
OfatumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Olaratumab.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Hepatitis A Vaccine.Investigational
OlokizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Olokizumab.Investigational
OmalizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Omalizumab.Approved, Investigational
OnartuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Otelixizumab.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hepatitis A Vaccine.Approved, Investigational
OzanezumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ozanezumab.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hepatitis A Vaccine.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Hepatitis A Vaccine.Approved, Investigational
PalivizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with Hepatitis A Vaccine.Approved, Investigational
PaquinimodThe risk or severity of adverse effects can be increased when Paquinimod is combined with Hepatitis A Vaccine.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Hepatitis A Vaccine.Approved
PatritumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Patritumab.Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Hepatitis A Vaccine.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Hepatitis A Vaccine.Approved, Investigational
PembrolizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Hepatitis A Vaccine.Approved, Investigational
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Hepatitis A Vaccine.Approved, Investigational
PertuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hepatitis A Vaccine.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Hepatitis A Vaccine.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Hepatitis A Vaccine.Approved, Investigational
Polatuzumab VedotinThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Polatuzumab Vedotin.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Hepatitis A Vaccine.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with Hepatitis A Vaccine.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Hepatitis A Vaccine.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Hepatitis A Vaccine.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Hepatitis A Vaccine.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hepatitis A Vaccine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Hepatitis A Vaccine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Hepatitis A Vaccine.Approved, Experimental, Investigational
PRO 140The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with PRO 140.Investigational
PRO-542The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with PRO-542.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Hepatitis A Vaccine.Approved, Investigational
R1507The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with R1507.Investigational
RacotumomabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Raxibacumab.Approved
ReslizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Reslizumab.Approved, Investigational
RI 624The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Hepatitis A Vaccine.Approved, Investigational
RilotumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Hepatitis A Vaccine.Approved
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Hepatitis A Vaccine.Approved
RobatumumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Robatumumab.Investigational
RomosozumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Romosozumab.Investigational
RontalizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rontalizumab.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Hepatitis A Vaccine.Approved
Sacituzumab govitecanThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sacituzumab govitecan.Investigational
SarilumabThe risk or severity of infection can be increased when Sarilumab is combined with Hepatitis A Vaccine.Approved, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Hepatitis A Vaccine.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Hepatitis A Vaccine.Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Hepatitis A Vaccine.Experimental, Investigational
SeribantumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Seribantumab.Investigational
SibrotuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sibrotuzumab.Investigational
SiltuximabThe risk or severity of adverse effects can be increased when Siltuximab is combined with Hepatitis A Vaccine.Approved, Investigational
SiplizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Siplizumab.Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Hepatitis A Vaccine.Approved, Investigational
SirukumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sirukumab.Investigational
SolanezumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Solanezumab.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Hepatitis A Vaccine.Approved, Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with Hepatitis A Vaccine.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Hepatitis A Vaccine.Approved, Investigational
SulesomabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sulesomab.Approved
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Hepatitis A Vaccine.Approved, Investigational
SYM001The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with SYM001.Investigational
TabalumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tabalumab.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Hepatitis A Vaccine.Approved, Investigational
TanezumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tanezumab.Investigational
TarextumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tarextumab.Investigational
TB-402The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with TB-402.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Technetium Tc-99m arcitumomab.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Hepatitis A Vaccine.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Hepatitis A Vaccine.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Hepatitis A Vaccine.Approved
TeplizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Teplizumab.Investigational
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Hepatitis A Vaccine.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Hepatitis A Vaccine.Approved
Tetanus Immune GlobulinThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tetanus Immune Globulin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hepatitis A Vaccine.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Hepatitis A Vaccine.Approved, Investigational
TildrakizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tildrakizumab.Approved
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Hepatitis A Vaccine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Hepatitis A Vaccine.Approved, Withdrawn
TNX-901The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Hepatitis A Vaccine.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Hepatitis A Vaccine.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Hepatitis A Vaccine.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Hepatitis A Vaccine.Approved, Investigational
TovetumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tovetumab.Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Hepatitis A Vaccine.Approved, Investigational
TralokinumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tralokinumab.Investigational
TrastuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Hepatitis A Vaccine.Approved, Investigational
TRC105The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with TRC105.Investigational
TremelimumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tremelimumab.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Hepatitis A Vaccine.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Hepatitis A Vaccine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Hepatitis A Vaccine.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Hepatitis A Vaccine.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Hepatitis A Vaccine.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Hepatitis A Vaccine.Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Hepatitis A Vaccine.Approved
VeltuzumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Veltuzumab.Investigational
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with Hepatitis A Vaccine.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Hepatitis A Vaccine.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Hepatitis A Vaccine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Hepatitis A Vaccine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Hepatitis A Vaccine.Approved, Investigational
VisilizumabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Visilizumab.Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Hepatitis A Vaccine.Investigational
VolociximabThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Volociximab.Investigational
XmAb 2513The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with XmAb 2513.Investigational
XTL-001The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with XTL-001.Investigational
Food Interactions
Not Available

References

General References
  1. MSDS [Link]
  2. WHO website [Link]
  3. product info [Link]
  4. Havrix Monograph [Link]
External Links
PubChem Substance
347911071
Drugs.com
Drugs.com Drug Page
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionPlasmodium Infections1
1CompletedPreventionRespiratory Synctial Virus1
2Active Not RecruitingPreventionVaccine Response Impaired1
2CompletedPreventionDiseases Caused by Measles, Mumps, Rubella and Varicella Viruses / Measles-Mumps-Rubella-Varicella Vaccine / Mumps / Rubella / Rubeola / Varicella1
2CompletedPreventionHealthy Volunteers / Norovirus / Norovirus, Prevention1
2CompletedPreventionHepatitis A1
2CompletedPreventionMumps / Rubella / Rubeola1
2CompletedPreventionResponse to Hepatitis A Vaccine1
2CompletedPreventionStreptococcal Infections / Streptococcus Pneumoniae and Nontypable Haemophilus Influenzae / Streptococcus Pneumoniae Vaccines1
2CompletedPreventionViral Hepatitis B1
2CompletedTreatmentBipolar Disorder (BD) / Depression / Human Immunodeficiency Virus (HIV) Infections / Schizoaffective Disorders / Schizophrenic Disorders / Substance Abuse1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2RecruitingBasic ScienceAstrocytomas / Gliomas / Oligodendrogliomas1
2TerminatedTreatmentBladder Cancers / Cancer, Breast / Malignant Neoplasm of Colon1
2, 3TerminatedPreventionInfections, Cytomegalovirus1
2, 3Unknown StatusPreventionHepatitis A / Varicella1
3CompletedPreventionCervical Intraepithelial Neoplasia (CIN) / Papillomavirus Infection1
3CompletedPreventionChickenpox / Hepatitis A / Mumps / Rubella / Rubeola1
3CompletedPreventionEncephalitis, Japanese B1
3CompletedPreventionEncephalitis, Japanese B / Hepatitis A1
3CompletedPreventionFlu caused by Influenza2
3CompletedPreventionHaemophilus Influenzae Infections / Pneumococcal Diseases / Streptococcal Infections / Streptococcus Pneumoniae1
3CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis1
3CompletedPreventionHepatitis A3
3CompletedPreventionHepatitis A Virus Infection1
3CompletedPreventionHepatitis A / Hepatitis A Vaccine1
3CompletedPreventionHepatitis A / Viral Hepatitis B3
3CompletedPreventionMeasles; Mumps; Rubella1
3CompletedPreventionMeningococcal Infections / Meningococcal Serogroup A, C, W-135, Y Diseases1
3CompletedPreventionMeningococcal Meningitis1
3CompletedPreventionMeningococcal Vaccines1
3CompletedPreventionMumps / Rubella / Rubeola2
3CompletedPreventionPneumonia & AOM Caused by S. Pneumoniae & H. Influenzae / Streptococcal Infections1
3CompletedPreventionStreptococcal Infections1
3Unknown StatusPreventionHepatitis A / Human Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1
3WithdrawnPreventionPapillomavirus Infections1
4Active Not RecruitingOtherMeningococcal Serogroup B1
4CompletedPreventionFlu caused by Influenza1
4CompletedPreventionHepatitis A7
4CompletedPreventionHepatitis A Virus2
4CompletedPreventionHepatitis A / Mumps / Rubella / Rubeola1
4CompletedPreventionHepatitis A / Viral Hepatitis B4
4CompletedPreventionHepatitis A / Viral Hepatitis B / Viral Hepatitis Vaccines1
4CompletedPreventionInflammation, Brain1
4CompletedPreventionParatyphoid Fever / Salmonella Typhi Infection2
4Enrolling by InvitationBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4Enrolling by InvitationPreventionHepatitis A1
4RecruitingPreventionHuman Papillomavirus Infections1
4TerminatedPreventionAcellular Pertussis / Diphtheria / Hepatitis A / Pertussis / Tetanus1
4Unknown StatusPreventionAntibody Response After Vaccination1
4Unknown StatusPreventionMeasurement of Immune Response to Hepatitis A / Measurement of Immune Response to Prevenar131
4Unknown StatusPreventionViral Hepatitis B2
4WithdrawnPreventionHepatitis A1
Not AvailableCompletedNot AvailableRheumatoid Arthritis / Spondylarthritis / Vasculitis1
Not AvailableCompletedPreventionHepatitis1
Not AvailableCompletedPreventionHepatitis A1
Not AvailableCompletedPreventionHepatitis A / Hepatitis C Viral Infection / Medication Adherence / Risk Behaviors / Substance Abuse, Intravenous / Viral Hepatitis B1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections4
Not AvailableCompletedTreatmentTransplant-Related Cancer1
Not AvailableRecruitingPreventionAutoimmune Rheumatologic Disease1
Not AvailableRecruitingPreventionCystic Fibrosis (CF) / Hepatitis A / Tuberculosis / Viral Hepatitis B1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionIntramuscular160 unit
SuspensionIntramuscular800 unit
SuspensionIntramuscular80 unit
LiquidIntramuscular500 unit
Injection, suspensionIntramuscular1440 [iU]/mL
Injection, suspensionIntramuscular720 [iU]/.5mL
SuspensionIntramuscular1440 unit
SuspensionIntramuscular720 unit
Injection, suspensionIntramuscular
SuspensionIntramuscular
Injection, suspensionIntramuscular25 [iU]/.5mL
Injection, suspensionIntramuscular50 [iU]/mL
SuspensionIntramuscular50 unit
Solution; suspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on April 23, 2018 23:14